Cassava Sciences (NASDAQ:SAVA - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.18) EPS for the quarter, Zacks reports.
Cassava Sciences Stock Down 2.9%
Cassava Sciences stock traded down $0.07 during midday trading on Friday, hitting $2.34. The company's stock had a trading volume of 610,026 shares, compared to its average volume of 914,831. The stock's 50-day moving average price is $2.15 and its 200-day moving average price is $2.08. Cassava Sciences has a 12 month low of $1.15 and a 12 month high of $33.98. The company has a market capitalization of $113.05 million, a PE ratio of -0.92 and a beta of -2.05.
Institutional Investors Weigh In On Cassava Sciences
Hedge funds and other institutional investors have recently bought and sold shares of the business. Jump Financial LLC bought a new stake in Cassava Sciences in the second quarter worth about $50,000. AQR Capital Management LLC purchased a new position in Cassava Sciences in the 1st quarter worth about $120,000. Marshall Wace LLP purchased a new position in Cassava Sciences in the 2nd quarter worth about $130,000. Strs Ohio purchased a new position in Cassava Sciences in the 1st quarter worth about $178,000. Finally, Goldman Sachs Group Inc. increased its stake in Cassava Sciences by 77.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 496,313 shares of the company's stock worth $744,000 after purchasing an additional 217,404 shares in the last quarter. 38.05% of the stock is currently owned by institutional investors.
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access